Back to top

Cognition Therapeutics reports Q3 EPS (6c), consensus (9c)

“The $30 million registered direct offering enables us to begin preparations for the next stage of development for zervimesine,” stated Lisa Riccia...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Cognition Therapeutics, Inc. (CGTX)